Tag: Eli Lilly

Dr John C. Lechleiter, farewell remarks: chairman, president, and chief executive officer Eli Lilly
Technical Briefing on Biodiversity: Lilly recent history in natural products research, part 1
Technical Briefing on Biodiversity: Lilly recent history in natural products research, part 2
Mr. David Brennan of AstraZeneca elected president of IFPMA

Other Tags

Access Access to antiretrovirals Access to Medicines Access to vaccines Africa AMR AMR Industry Alliance Anti-Counterfeit Antibiotics antimicrobial resistance antivirals Biosimilars Biotherapeutic Medicines Biotherapeutics Cancer Clinical Trials Code of Practice collaboration Counterfeit Medicines Counterfeits COVID-19 COVID-19 vaccines Dementia Developing World Diabetes Economic footprint Epidemics Ethics Event Highlights Fake Medicines Fakes Falsified Medicines Fight the Fakes Flu Global Health global health security harmonization Health Health Partnerships HIV/AIDS IFPMA IFPMA Assembly IFPMA Statement Immunization Incremental Innovation Influenza Infographic Infographics Innovation Innovation ecosystem Intellectual Property IP Malaria MDGs Medicines Mental and Neurological Disorders NCDs Neglected Tropical Diseases News Releases Non-Communicable Diseases Novel Coronavirus (COVID-19) NTDs pandemic Pandemic Influenza Pandemic preparedness pandemics partnership Partnerships Pharma Pharmacovigilance Position Paper Prevention Publications Public Health Quality R&D Regulatory regulatory systems Related Links Research Safety SDGs Seasonal Influenza Statements Supply chain Sustainable Development Goals Sustainable Innovation trade Treatments Tuberculosis UHC Universal Health Coverage Vaccine Vaccines Value of Innovation Videos WHA WHO WIPO Women’s Cancers